Drug Trial Radar · NCT03245190
Study of Chiauranib in Patients With Advanced Hepatocellular Carcinoma
Last checked: Nov 19, 2026Latest source record: Jun 18, 2021 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
27
Actual
Start
Apr 28, 2018
Primary completion
Nov 1, 2019
Study completion Nov 1, 2019
Sponsor
- Lead sponsor
- Chipscreen Biosciences, Ltd.Industry
- Sponsor type
- Industry
- First posted
- Aug 10, 2017
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Chiauranib, which simultaneously targets against VEGFR/Aurora B/CSF-1R, several key kinases involved in tumor angiogenesis, tumor cell mitosis, and chronic inflammatory microenvironment.
Conditions
- Hepatocellular Carcinoma
Interventions
ChiauranibDrug
50mg, orally once daily
Primary outcomes
What the sponsor says the trial is designed to measure.
- 16 weeks progression-free rate (16W-PFR)Time frame: Up to a minimum 16 weeks after the last participant's first dose, or progression, or died, whichever came first
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Zhongshan Hospital of Fudan University
Shanghai, Shanghai Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.